


ZyVersa Therapeutics, Inc. (Fri, May 17, 2024)

Buy candidate since Apr 30, 2024

Loss -15.18%

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **0.564**
#6779/ 29925

Trend: Buy
MV Long: Buy
MV Short: Sell
Pivot: Sell
Volume: Buy
MACD: Sell

Tech commentaries:

The **ZyVersa Therapeutics, Inc.** stock price fell by **-7.67%** on the last day (Friday, 17th May 2024) from **\$4.86** to **\$4.49**. It has now fallen 4 days in a row. During the last trading day the stock fluctuated **14.16%** from a day low at **\$4.45** to a day high of **\$5.08**. The price has fallen in 6 of the last 10 days and is down by **-17.67%** for this period. Volume has increased on the last day by **72 thousand** shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, **96 thousand** shares were bought and sold for approximately **\$428.84 thousand**.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise **233.21%** during the next 3 months and, with a 90% probability hold a price between **\$6.30** and **\$23.70** at the end of this 3-month period.

The **ZyVersa Therapeutics, Inc.** stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately **\$5.10**. On a fall, the stock will find some support from the long-term average at approximately **\$2.84**. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on **Tuesday, May 07, 2024**, and so far it has fallen -30.65%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). **ZyVersa Therapeutics, Inc.** gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days. On the upside the stock meets some resistance from accumulated volume at **\$4.99**, **\$5.29** and **\$5.45**.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved **\$0.630** between high and low, or **14.16%**. For the last week, the stock has had daily average volatility of **7.71%**.

ZyVersa Therapeutics, Inc. holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold/Accumulate candidate.

Risk: Very High

Evaluation: Hold/Accumulate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.